Chairman, President and CEO
Ben founded QPS in 1995. QPS has DMPK laboratories in Newark, Delaware, clinical phase 1 unit in Springfield, Missouri, clinical/bioanalytical labs in Taipei, Taiwan and sales office in many states of US. Under his guidance; QPS is recognized as a premier Contract Research Organization. QPS received Philadelphia 100 Award of 2005 - An award organized by Wharton SBDC and its selection was based on the top fast growing 100 companies in the tri-state area during 2002-2004. Dr. Benjamin Chien obtained his Ph.D. in analytical chemistry (mass spectrometry) from the University of Michigan at Ann Arbor with Prof. David M. Lubman. Ben is the co-inventor of a novel Ion Trap/Time-of-Flight Mass Spectrometer. Ben began his pharmaceutical career at DuPont Merck Pharmaceutical Co. in the Drug Metabolism and Pharmacokinetics Section, where he built the LC/MS/MS group dedicated to supporting drug discovery, preclinical and clinical studies. In 1996, Ben received the Summit Award, the highest level of achievement at DuPont Merck for his dedicated contribution to the development of Efavirenz, an anti-viral drug approved by the FDA for the treatment of HIV disease.

Chief Financial Officer
T. Ben Hsu, PhD, MBA, joined QPS in 2003 as Vice President, Finance and Control and was promoted to CFO in 2005. Ben was with Aventis Behring, a division of Aventis S.A., from 1999 to 2003 and was Director of Global Finance Administration. Prior to joining Aventis, he was with Lyondell Chemical Company (previously ARCO Chemical Company) where he held posts in a variety of functions including R&D, licensing, finance, and planning and control. Ben received his BS degree from National Taiwan University and his Masters and PhD degrees from the University of Delaware, all in chemical engineering. He also earned an MBA in general administration and finance from Drexel University.

VP of Operations
Kumar Ramu, PhD, joined QPS in 2000 as Vice President of Operations. He previously served as a Group Leader at CoCensys and Purdue Pharma, in the discovery, preclinical, and clinical drug development departments of DMPK, as well as in toxicology and pharmaceutical sciences, where he was involved in ERC/IND/CTX filings and regulatory meetings. Kumar received his PhD in medicinal chemistry from the University of Mississippi and obtained his post-doctoral training in toxicology from the University of Texas at Austin.

Vice President of Global DMPK
Shang-Ying Peter King, PhD, joined QPS in 2005 as Vice President of Global DMPK. Peter has over 21 years of pharmaceutical industry experience supporting discovery and development of new chemical entities. Prior to joining QPS, Peter was the Director of Pre-Clinical Pharmacokinetics, US DMPK with Aventis/Sanofi-Aventis Pharmaceuticals. Before working at Aventis, Peter had management responsibilities in clinical and preclinical pharmacokinetics at Wyeth-Ayerst Research, at Cephalon, Inc.and at DuPont Pharmaceuticals. Peter obtained his PhD in pharmaceutics from the State University of New York at Buffalo.

Senior Director of Discovery and Preclinical Development
Helen Shen, PhD, joined QPS in 2002 as Director of Discovery and Preclinical Development and was promoted to Senior Director of Discovery and Preclinical Development in 2005. Prior to joining QPS, Helen held the position of Principal Research Scientist at DuPont Pharmaceuticals where she led a number of ADME teams and was responsible for conducting DMPK activities for ERC/IND filing as well as other non-clinical activities for IND. Helen received her PhD in pharmaceutical chemistry from the University of California at San Francisco and her post-doctoral training in pharmaceutics from the University of Washington.

Director of Autoradiography
Eric Solon, PhD, joined QPS in 2002 as Director of Autoradiography. Prior to joining QPS, Eric served as a Senior Scientist at DuPont Pharmaceuticals, where he coordinated DMPK activities for ERC/IND filings and implemented both macro- and micro-autoradiography techniques to support drug discovery and development. Before joining DuPont, he held various scientific posts at Ciba-Geigy Pharmaceuticals, Novartis, and Schering-Plough Research Institute. Eric received his PhD in Molecular Biology/Pathology from Rutgers University. Eric is currently the President-Elect and Secretary of the Society for Whole-body Autoradiography.

Director of Discovery and Preclinical Development
Bruce Aungst, PhD, joined QPS in 2004 as Associated Director of Discovery and Preclinical Development and was promoted to Director of Discovery and Preclinical Development in 2006. His responsibilities include the design of experiments, creating study protocols, managing lab resources and projects, creating study reports, and enabling clients to fulfill their discovery and preclinical ADME and pharmacokinetics project needs. In previous positions at DuPont Pharmaceuticals and Bristol Myers Squibb, he managed multidisciplinary ADME/Biopharmaceutics teams. His work has led to the identification and discovery of formulations for improving oral absorption and bioavailability. Bruce obtained his PhD in pharmaceutics from the State University of New York at Buffalo.

Associate Director of in vitro and in vivo Metabolism
Ronghua Wang, PhD, joined QPS in 2005 as Associate Director of in vitro and in vivo Metabolism. Prior to joining QPS, he was a senior scientist at Vertex Pharmaceuticals and Millennium Pharmaceuticals responsible for the metabolism of drug discovery and development projects. He has extensive experience in structure elucidation of metabolites of drugs and drug candidates using mass spectrometry and NMR spectrometry. Ronghua received his PhD in pharmaceutical sciences from the University of Rhode Island.

Research Scientist
Foster P. Brown joined QPS in February 2003 as a Research Scientist. As a Staff Scientist for DuPont Pharmaceuticals, Foster helped create the first in-life animal research group within DuPont and in 1992, became the supervisor of that group performing absorption, distribution, metabolism and excretion studies (ADME) on various animal models.

Animal Research and Facility Manager
Brad Willis, DVM, joined QPS in August of 2002 as the Attending Veterinarian and Supervisor of Animal Resources. Prior to joining QPS, he was a Research Associate and Laboratory Manager for the Department of Emergency Medicine at the Louisiana State University Health Sciences Center in Shreveport. He has jointly published several papers primarily involving ischemia/reperfusion studies and activation of leukocytes and their effects on vascular [primarily pulmonary] endothelium in rodents. Brad also served as Consultant Veterinarian to and IACUC Chairman for Fabgennix, Inc. Brad received his DVM from Kansas State University.

Lab Manager of Autoradiography
Alfred Lordi, MS, joined QPS in 2002 as the Manager of Autoradiography. Prior to joining QPS, Alfred worked in the toxicology departments of Bio-Dynamics, Exxon Biomedical, and Schering-Plough Research Institute where he coordinated DMPK study activities in whole-body autoradioluminography (WBA), microautoradiography, tissue distribution, and human radio-excretion studies. Alfred received his BS in animal science from Rutgers University and his MS in biology from Seton Hall University. Alfred is currently the Secretary of the Society for Whole-Body Autoradiography.

Research Scientist in Autoradiography
Nina S. Rebmann, BA, joined QPS in 2005 as a Research Scientist in the Autoradiography laboratory. Prior to joining QPS, Nina served as the lead scientist in whole-body autoradiography and was instrumental in establishing the WBA capability for Aventis/Sanofi Aventis US. She was also a member of the Global QWBA Integration Team. Prior to Aventis, Nina was the lead scientist for WBA at Novartis Pharmaceuticals and was a member of the Global PCS Network for WBA. She has also worked at Princeton University in the Department of Psychology and at Wyeth-Ayerst Research in the cardiovascular department. She received her BA in biology at Douglass College (Rutgers University). Nina is currently the Treasurer of the Society for Whole-Body Autoradiography (US).

Senior Director of Operations
Yuen-Shek Chen, PhD, joined QPS in 1998 as Senior Bioanalytical Scientist. He is currently serving as Senior Director of Operations where he is responsible for all bioanalytical activities. During his tenure with QPS, Yuen-Shek has been responsible for setting up a dedicated DMPK bioanalytical unit and is also instrumental in setting up the QPS-Taiwan operations. Yuen-Shek received his PhD in organic chemistry from the University of Michigan at Ann Arbor and his post-doctoral training from the University of Illinois at Urbana-Champaign.

Director of Bioanalytical Research
Yongdong Zhu, PhD, joined QPS in 1999 as Research Scientist and was promoted to Director of Bioanalytical Research in 2003. Prior to joining QPS, Yongdong held various scientific positions in Yanshan Petrochemical Corporation including Senior Research Chemist and Group Leader. Yongdong received his PhD in analytical chemistry from the University of Michigan at Ann Arbor.

Head of Analytical Research
Jamie J. Zhao, PhD, joined QPS in 2006 as Head of Analytical Research. Prior to joining QPS, Jamie was a Senior Research Fellow at Merck Research Laboratories and a Senior Research Scientist at Advanced Bioanalytical Services, Inc. (now Advion BioSciences). Jamie has authored approximately 25 peer-review journal publications and over 50 scientific meeting presentations/abstracts in the areas of mass spectrometry, bioanalytical, and pharmacokinetics. Jamie received his PhD in analytical chemistry from the University of Michigan at Ann Arbor and his post-doctoral training from Purdue University.

Director of Translational Medicine
Hui Zhang, MD, joined QPS in 2002 with extensive research experience in hepatology/hematology, neuroscience and cancer at Materia Medica, Mt. Sanai Medical Center, Cornell University Medical College, and DuPont Pharmaceuticals. Since joining QPS, Hui has been involved in the Immunoanalytical/ Biomarker area operational setup and assay development. She is currently Associate Director in the Immunoanalytical group.

QA Manager, Head of US QA Department
Wendy Finan, BS, joined QPS in April 2002 as a Senior Quality Assurance Auditor and was promoted to QPS Quality Assurance Manager (US) in September 2007. Wendy began her career at DuPont Pharmaceuticals in 1989 in Drug Metabolism and Pharmacokinetics, and since then, she has attained over 18 years of pharmaceutical industry experience supporting discovery, method development, GCP, and GLP tox studies.

Executive Director of Strategic Planning and Marketing
Zamas Lam, PhD, joined QPS in 2000 as Account Manager and is currently serving as the Senior Director of Specialized Client Development. Prior to joining QPS, Zamas held various scientific and business positions at the DuPont Corporation. Zamas received his PhD in chemistry from the University of British Columbia and his post-doctoral training from Harvard University.

Senior Director of Business Development
Jerry Gromelski joined QPS in 2002 as Director of Business Development and was promoted to Senior Director of Business Development in 2007. A classically trained pharmacologist, he is currently responsible for client services in the southeast region of the United States. Prior to joining QPS, Jerry has 27 years of experience in the CRO industry holding technical, operational, and business development positions.

Executive Director & Head of Business Development
Livia Legg, MS, joined QPS in 2002 as Director of Business Development and was promoted to Executive Director & Head of Business Development in 2007 and is responsible for all Business Development Activities. Livia started her career in business development at Merck Pharmaceutical Co. and subsequently worked for an independent laboratory in the areas of Drug Discovery and Preclinical Development. She earned her MS degree from the University of New Hampshire.

Senior Director of Business Development
Robert P. Kokka, DrPH, joined QPS in 2003 as Director of Business Development and was promoted to Senior Director of Business Development in 2007. He is presently responsible for client services in the western regions of the United States. Prior to joining QPS, Robert served as Director of Scientific Affairs and Technical Services for Roche Molecular Systems (Hoffmann-La Roche) and Bayer/Chiron Nucleic Acid Diagnostics. Robert earned his BS degree from the University of California, Davis and a DrPH in biomedical laboratory sciences from the University of California at Berkeley.

Director of Business Development
Lily Rosa, MS, joined QPS in 2006 as Director of Business Development. She is presently responsible for client services in the Midwest and MA regions of the United States. Prior to joining QPS, Lily has had business development and technical responsibilities at various organizations including Ambion, Affymetrix, Procter & Gamble Pharmaceuticals, and Cincinnati Children's Hospital. She earned her MS degree from Iowa State University.


Vice President of Translational Medicine
LingSing K. Chen, PhD, joined QPS in 2005 as Executive Director of Molecular Biology and is currently serving as the Vice President of Translational Medicine. Prior to joining QPS, LingSing held various positions at Wyeth Pharmaceuticals including Associate Director of Molecular and Cell Biology, Head of Ion Channel Molecular Biology, and Head of Wyeth-PanLabs natural product screening collaboration. LingSing has served as senior advisor to Industrial Technology Research Institute (ITRI) in Taiwan since 1999 where she also helped establish the Biomedical Engineering Center to foster the growth of the biotechnology industry in Taiwan. Dr. Chen received her MA and PhD in molecular biology from Princeton University and her BS in biology from National Taiwan University.

Consulting Director
Check Y. Quon, PhD, MBA, joined QPS as Consulting Director in 2004. Prior to joining QPS, he was the Executive Director of Drug Metabolism and Pharmacokinetics at DuPont Pharmaceuticals Co. where he was responsible for the preclinical and clinical drug metabolism and pharmacokinetics of all new chemical entities in the cancer, cardiovascular, HIV, neurology, and inflammatory diseases therapeutic areas. Check and his team have successfully filed and gained approval of eight NDA's and one MAA, submitted over 50 IND's and 15 CTX's, and supported the nomination of over 100 drug candidates. Check has published more than 50 peer-reviewed manuscripts, more than 80 abstracts and three book chapters in the areas of preclinical and clinical drug metabolism, toxicokinetics, preclinical and clinical pharmacokinetics and pharmacodynamics, clinical pharmacology, and cardiovascular pharmacology. Check received his PhD in pharmacology from the University of California at Los Angeles and his post-doctoral training in oncology at the McArdle Laboratory for Cancer Research at the University of Wisconsin. He also earned an MBA from the University of Delaware.